Profile
Paolo Cionini worked at LEO Laboratories Ltd. (Ireland) as General Manager-Italy.
Mr. Cionini worked at Almirall SA as Chief Commercial Officer-Europe & International.
Mr. Cionini completed undergraduate studies at Università degli Studi di Modena e Reggio Emilia.
Former positions of Paolo Cionini
| Companies | Position | End |
|---|---|---|
LEO Laboratories Ltd. (Ireland)
LEO Laboratories Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Part of LEO Fondet, LEO Laboratories Ltd. (Ireland) is a Denmark-based, Irish research-driven pharmaceutical company specializing in medical dermatology. The company has a longstanding manufacturing presence in Ireland since 1958. LEO Laboratories Ltd. focuses on improving skin health and provides dermatological treatments to patients in over 130 countries. The company emphasizes ethical business practices, transparency in clinical trials, and support for patients, healthcare professionals, and the NHS. | Corporate Officer/Principal | - |
| ALMIRALL, S.A. | Corporate Officer/Principal | - |
Training of Paolo Cionini
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
Almirall SA
Almirall SA Pharmaceuticals: MajorHealth Technology Engages in the development, manufacture and sale of pharmaceuticals | Health Technology |
Università degli Studi di Modena e Reggio Emilia
Università degli Studi di Modena e Reggio Emilia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LEO Laboratories Ltd. (Ireland)
LEO Laboratories Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Part of LEO Fondet, LEO Laboratories Ltd. (Ireland) is a Denmark-based, Irish research-driven pharmaceutical company specializing in medical dermatology. The company has a longstanding manufacturing presence in Ireland since 1958. LEO Laboratories Ltd. focuses on improving skin health and provides dermatological treatments to patients in over 130 countries. The company emphasizes ethical business practices, transparency in clinical trials, and support for patients, healthcare professionals, and the NHS. | Health Technology |
- Stock Market
- Insiders
- Paolo Cionini
















